Baxter; Andrew Douglas
Patent Applications and Registrations
Patent applications and USPTO patent grants for Baxter; Andrew Douglas.The latest application filed is for "srpk1 inhibitors".
Company Profile
1.29.41
- Baxter; Andrew Douglas - Horsham GB
- Baxter; Andrew Douglas - Horsham Sussex GB
- Baxter; Andrew Douglas - West Sussex GB
- Baxter; Andrew Douglas - Cambridge N/A GB
- Baxter; Andrew Douglas - London GB
- Baxter; Andrew Douglas - Sandwich GB
- Baxter; Andrew Douglas - Essex GB
- Baxter; Andrew Douglas - Bury St. Edmunds GB
Patent Activity
| Patent | Date |
|---|---|
| SRPK1 inhibitors Grant 11,420,969 - Baxter , et al. August 23, 2 | 2022-08-23 |
| Srpk1 Inhibitors App 20200270249 - Baxter; Andrew Douglas ; et al. | 2020-08-27 |
| Anti-angiogenic compounds Grant 9,975,860 - Kennedy , et al. May 22, 2 | 2018-05-22 |
| Anti-angiogenic compounds Grant 9,815,788 - Kennedy , et al. November 14, 2 | 2017-11-14 |
| Anti-angiogenic Compounds App 20170050930 - KENNEDY; Breandan Noel ; et al. | 2017-02-23 |
| Anti-Angiogenic Compounds App 20160326122 - KENNEDY; Breandan ; et al. | 2016-11-10 |
| Anti-angiogenic compounds Grant 9,388,138 - Kennedy , et al. July 12, 2 | 2016-07-12 |
| Anti-angiogenic Compounds App 20150218100 - Kennedy; Breandan Douglas ; et al. | 2015-08-06 |
| Crystallisation and purification of glycopyrronium bromide Grant 8,846,954 - Baxter , et al. September 30, 2 | 2014-09-30 |
| Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain App 20120219592 - Brew; John ; et al. | 2012-08-30 |
| Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain Grant 8,188,150 - Brew , et al. May 29, 2 | 2012-05-29 |
| Use of bupropion metabolites for the treatment of inflammatory disorders Grant 8,030,357 - Brew , et al. October 4, 2 | 2011-10-04 |
| Glycopyrronium salts and their therapeutic use Grant 7,915,303 - Baxter March 29, 2 | 2011-03-29 |
| Morpholine dopamine agonists Grant 7,902,188 - Allerton , et al. March 8, 2 | 2011-03-08 |
| Ester derivatives of rhein and their therapeutic use Grant 7,728,035 - Baxter , et al. June 1, 2 | 2010-06-01 |
| Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain App 20100016357 - Baxter; Andrew Douglas | 2010-01-21 |
| Use of Bupropion Metabolites for the Treatment of Inflammatory Disorders App 20090318562 - Brew; John ; et al. | 2009-12-24 |
| Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain App 20090306216 - Brew; John ; et al. | 2009-12-10 |
| Use of Buprenorphine or N-Alkylated Derivatives Thereof for Wound Healing App 20090270437 - Baxter; Andrew Douglas ; et al. | 2009-10-29 |
| Morpholine Dopamine Agonists App 20090270384 - Allerton; Charlotte Moria Norfor ; et al. | 2009-10-29 |
| Morpholine dopamine agonists Grant 7,576,081 - Allerton , et al. August 18, 2 | 2009-08-18 |
| Methods and Compositions for the Treatment of Pruritus App 20090093509 - Nazir; Tahir ; et al. | 2009-04-09 |
| Glycopyrronium Salts and Their Therapeutic Use App 20090062372 - Baxter; Andrew Douglas | 2009-03-05 |
| Benzoxazocines and Their Therapeutic Use App 20090012178 - Baxter; Andrew Douglas | 2009-01-08 |
| Treatment of Inflammatory Disorders and Pain App 20080306162 - Baxter; Andrew Douglas ; et al. | 2008-12-11 |
| Dihydroxyanthraquinones and Their Use App 20080234258 - Baxter; Andrew Douglas ; et al. | 2008-09-25 |
| Crystallisation and Purification of Glycopyrronium Bromide App 20080227988 - Baxter; Andrew Douglas ; et al. | 2008-09-18 |
| Treatment of Inflammatory Disorders and Pain App 20080096971 - Baxter; Andrew Douglas ; et al. | 2008-04-24 |
| Morpholine dopamine agonists Grant 7,323,462 - Allerton , et al. January 29, 2 | 2008-01-29 |
| Ester derivatives of rhein and their therapeutic use App 20070185036 - Baxter; Andrew Douglas ; et al. | 2007-08-09 |
| Treatment of inflammatory disorders and pain using beta-aminoalcohols App 20070179181 - Baxter; Andrew Douglas ; et al. | 2007-08-02 |
| Crystalline forms of (+)- and (-) erythro-mefloquine hydrochloride App 20070078161 - Sinden; Kenneth Walter ; et al. | 2007-04-05 |
| Use of non-opiates for the potentation of opiates App 20070043112 - Brew; John ; et al. | 2007-02-22 |
| Use of ifenprodril in the treatment of pain App 20070043111 - Brew; John ; et al. | 2007-02-22 |
| Morpholine Dopamine Agonists App 20060235016 - Allerton; Charlotte Moria Norfor ; et al. | 2006-10-19 |
| Triazole compounds useful in therapy Grant 7,084,145 - Armour , et al. August 1, 2 | 2006-08-01 |
| Resolution of mefloquine with o,o-di-p-aroyltartaric acid App 20060111573 - Baxter; Andrew Douglas ; et al. | 2006-05-25 |
| Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction App 20060052435 - Van der Graaf; Pieter Hadewijn ; et al. | 2006-03-09 |
| Novel benzoxazocines and their therapeutic use App 20060019940 - Baxter; Andrew Douglas ; et al. | 2006-01-26 |
| Hydroxamic and carboxylic acid derivatives Grant 6,933,306 - Hannah , et al. August 23, 2 | 2005-08-23 |
| Hydroxamic acid derivatives App 20040266764 - Hannah, Duncan Robert ; et al. | 2004-12-30 |
| Morpholine dopamine agonists App 20040259874 - Allerton, Charlotte Moria Norfor ; et al. | 2004-12-23 |
| Selective MMP inhibitors having reduced side-effects Grant 6,818,622 - Bird , et al. November 16, 2 | 2004-11-16 |
| Hydroxamic acid derivatives Grant 6,809,100 - Hannah , et al. October 26, 2 | 2004-10-26 |
| Hydroxamic and carboxylic acid derivatives App 20040176362 - Batty, Duncan ; et al. | 2004-09-09 |
| Hydroxamic acid derivatives Grant 6,787,536 - Hannah , et al. September 7, 2 | 2004-09-07 |
| Triazole compounds useful in therapy App 20040162278 - Armour, Robert Duncan ; et al. | 2004-08-19 |
| Hydroxamic and carboxylic acid derivatives App 20040127717 - Montana, John Gary ; et al. | 2004-07-01 |
| Hydroxamic and carboxylic acid derivatives Grant 6,734,189 - Batty , et al. May 11, 2 | 2004-05-11 |
| Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity Grant 6,706,719 - Baxter , et al. March 16, 2 | 2004-03-16 |
| Hydroxamic and carboxylic acid derivatives Grant 6,680,338 - Montana , et al. January 20, 2 | 2004-01-20 |
| Hydroxamic And Carboxylic Acid Derivatives App 20030236416 - Montana, John Gary ; et al. | 2003-12-25 |
| Hydroxamic acid derivatives App 20030216404 - Hannah, Duncan Robert ; et al. | 2003-11-20 |
| Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity App 20030207889 - Owen, David Alan ; et al. | 2003-11-06 |
| Hydroxamic and carboxylic acid derivatives App 20030092727 - Hannah, Duncan Robert ; et al. | 2003-05-15 |
| Hydroxamic and carboxylic acid derivatives App 20030032652 - Batty, Duncan ; et al. | 2003-02-13 |
| Hydroxamic and carboxylic acid derivatives App 20030022893 - Baxter, Andrew Douglas ; et al. | 2003-01-30 |
| Hydroxamic and carboxylic acid derivatives Grant 6,506,773 - Hannah , et al. January 14, 2 | 2003-01-14 |
| Hydroxamic and carboxylic acid derivatives Grant 6,469,020 - Batty , et al. October 22, 2 | 2002-10-22 |
| Hydroxamic and carboxylic acid derivatives Grant 6,465,468 - Baxter , et al. October 15, 2 | 2002-10-15 |
| Hydroxamic acid derivatives App 20020037900 - Hannah, Duncan Robert ; et al. | 2002-03-28 |
| Selective MMP inhibitors having reduced side-effects App 20020035065 - Bird, John ; et al. | 2002-03-21 |
| Hydroxamic and carboxylic acid derivatives App 20020022635 - Hannah, Duncan Robert ; et al. | 2002-02-21 |
| Hydroxamic and carboxylic acid derivatives App 20020013333 - Batty, Duncan ; et al. | 2002-01-31 |
| Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity Grant 6,118,001 - Owen , et al. September 12, 2 | 2000-09-12 |
| Peptidyl compounds Grant 6,048,841 - Baxter , et al. April 11, 2 | 2000-04-11 |
| Peptidyl compounds having MMP and TNF inhibitory activity Grant 5,955,435 - Baxter , et al. September 21, 1 | 1999-09-21 |
| Quinolones and their therapeutic use Grant 5,891,878 - Beasley , et al. April 6, 1 | 1999-04-06 |
| Quinolones and their therapeutic use Grant 5,753,666 - Beasley , et al. May 19, 1 | 1998-05-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 